Ipilimumab in a Phase II trial of melanoma patients with brain metastases

In a Phase II clinical study enrolling individuals with melanoma brain metastases, 51 asymptomatic patients (cohort A) and 21 on a stable steroid dose (cohort B) received 4 courses of 10 mg/kg intravenous ipilimumab (induction), then (at 24 weeks) maintenance therapy with the same dose of ipilimumab...

Descripción completa

Detalles Bibliográficos
Autor principal: Margolin, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494644/
https://www.ncbi.nlm.nih.gov/pubmed/23170278
http://dx.doi.org/10.4161/onci.20687
_version_ 1782249421858144256
author Margolin, Kim
author_facet Margolin, Kim
author_sort Margolin, Kim
collection PubMed
description In a Phase II clinical study enrolling individuals with melanoma brain metastases, 51 asymptomatic patients (cohort A) and 21 on a stable steroid dose (cohort B) received 4 courses of 10 mg/kg intravenous ipilimumab (induction), then (at 24 weeks) maintenance therapy with the same dose of ipilimumab every 12 weeks. Disease control rate at 12 weeks was 18% (according to the modified WHO criteria) and 26% (according to the immune-related response criteria) in cohort A (median survival = 7 mo) and 5% and 10% in cohort B (median survival = 4 mo). Toxicities were as previously reported for ipilimumab patients without brain metastases.
format Online
Article
Text
id pubmed-3494644
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946442012-11-20 Ipilimumab in a Phase II trial of melanoma patients with brain metastases Margolin, Kim Oncoimmunology Author's View In a Phase II clinical study enrolling individuals with melanoma brain metastases, 51 asymptomatic patients (cohort A) and 21 on a stable steroid dose (cohort B) received 4 courses of 10 mg/kg intravenous ipilimumab (induction), then (at 24 weeks) maintenance therapy with the same dose of ipilimumab every 12 weeks. Disease control rate at 12 weeks was 18% (according to the modified WHO criteria) and 26% (according to the immune-related response criteria) in cohort A (median survival = 7 mo) and 5% and 10% in cohort B (median survival = 4 mo). Toxicities were as previously reported for ipilimumab patients without brain metastases. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494644/ /pubmed/23170278 http://dx.doi.org/10.4161/onci.20687 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Margolin, Kim
Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title_full Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title_fullStr Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title_full_unstemmed Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title_short Ipilimumab in a Phase II trial of melanoma patients with brain metastases
title_sort ipilimumab in a phase ii trial of melanoma patients with brain metastases
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494644/
https://www.ncbi.nlm.nih.gov/pubmed/23170278
http://dx.doi.org/10.4161/onci.20687
work_keys_str_mv AT margolinkim ipilimumabinaphaseiitrialofmelanomapatientswithbrainmetastases

Ejemplares similares